Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NewAmsterdam Pharma Company ( (NAMS) ) has shared an update.
On March 2, 2026, NewAmsterdam Pharma posted an updated corporate investor presentation detailing recent clinical, commercial, and financial progress around its lead candidate obicetrapib. The company highlighted Phase 2 and Phase 3 data indicating significant LDL-C reductions of roughly 35–40% as monotherapy and about 50% in combination with ezetimibe, plus a roughly 45% cut in Lp(a) and a 21% exploratory one-year MACE reduction favoring obicetrapib, alongside broader biomarker effects including ApoB, non-HDL-C, LDL-P, HDL-C, and markers of glycemic control and renal function.
The presentation underscored obicetrapib’s potential to serve a substantial cardiometabolic market, especially the approximately 30 million U.S. patients on lipid-lowering drugs who remain above LDL-C goals due to product limitations and access hurdles. Management also pointed to strengthened fundamentals, including comprehensive patent protection until mid-2043, publication of key BROOKLYN, BROADWAY and TANDEM Phase 3 results in leading journals, expansion of commercial and medical affairs infrastructure in Europe and the U.S., and an expected year-end 2025 cash balance of about $729 million intended to support a prospective U.S. launch and regulatory milestones such as a planned EMA submission in 2025.
The most recent analyst rating on (NAMS) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
Overall score reflects strong balance-sheet stability and a supportive recent corporate update, offset by weak profitability and persistent cash burn that dominate financial risk. Technicals are moderately constructive, while valuation remains challenged due to ongoing losses and no dividend.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. is a biopharmaceutical company focused on cardiometabolic diseases, developing oral lipid-lowering therapies to address unmet needs in patients with hypercholesterolemia. Its lead asset, obicetrapib, a once-daily CETP inhibitor, is being positioned as an adjunct to statins for patients who are not achieving LDL-C targets, with potential use in combination regimens and a large U.S. market opportunity among roughly 30 million treated but uncontrolled patients.
Average Trading Volume: 810,910
Technical Sentiment Signal: Buy
Current Market Cap: $4.08B
For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.